Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tapentadol (Palexia®) oral solution cannot be endorsed for use within NHS Wales for the relief of moderate to severe acute pain in children from 2 years of age and in adults, which can be adequately managed only with opioid analgesics. |
||
|
||
Medicine details |
||
| Medicine name | tapentadol (Palexia®) | |
| Formulation | 20 mg/ml oral solution | |
| Reference number | 3970 | |
| Indication | For the relief of moderate to severe acute pain in children from 2 years of age and in adults, which can be adequately managed only with opioid analgesics |
|
| Company | Grunenthal Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 07/11/2018 | |